Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe

World Journal of Gastroenterology

Volumn 21, Issue 6, 2015, Pages 1728-1737

  Rencz, Fanni ^a,b   Péntek, Márta ^a   Bortlik, Martin ^c   Zagorowicz, Edyta ^d   Hlavaty, Tibor ^e   ͆liwczyński, Andrzej ^f   Diculescu, Mihai M ^g   Kupcinskas, Limas ^h   Gecse, Krisztina B ⁱ   Gulácsi, László ^a   Lakatos, Peter L ⁱ  

^a Institute of Entrepreneurship and Innovation   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c CHARLES UNIVERSITY   (Czech Republic)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^h LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

ⁱ SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Access; Biological therapy; Crohn's disease; Europe, Central and Eastern; Inflammatory bowel diseases; Ulcerative colitis

Indexed keywords

ADALIMUMAB; GOLIMUMAB; INFLIXIMAB; ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT;

ARTICLE; BIOLOGICAL THERAPY; CENTRAL EUROPEAN; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG COST; DRUG INDUSTRY; EASTERN EUROPE; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; INFLAMMATORY BOWEL DISEASE; MAINTENANCE THERAPY; REIMBURSEMENT; ULCERATIVE COLITIS; CLINICAL PRACTICE; COLITIS, ULCERATIVE; ECONOMICS; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; IMMUNOLOGY; PREVALENCE; TREATMENT OUTCOME; TRENDS;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG COSTS; EUROPE, EASTERN; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; PRACTICE PATTERNS, PHYSICIANS'; PREVALENCE; TREATMENT OUTCOME;

EID: 84922747685     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i6.1728     Document Type: Article

References (57)

1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785-1794 [PMID: 21530745 DOI: 10.1053/j.gastro.2011.01.055]
2. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012; 380: 1606-1619 [PMID: 22914296 DOI: 10.1016/S0140-6736(12)60150-0]
3. Nielsen OH, Bjerrum JT, Seidelin JB, Nyberg C, Ainsworth M. Biological treatment of Crohn's disease. Dig Dis 2012; 30 Suppl 3: 121-133 [PMID: 23295703 DOI: 10.1159/000342738]
4. Danese S, Colombel JF, Peyrin-Biroulet L, Rutgeerts P, Reinisch W. Review article: the role of anti-TNF in the management of ulcerative colitis - past, present and future. Aliment Pharmacol Ther 2013; 37: 855-866 [PMID: 23489068 DOI: 10.1111/apt.12284]
5. Brodszky V, Baji P, Balogh O, Péntek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ 2014; 15 Suppl 1: S65-S71 [PMID: 24832837 DOI: 10.1007/s10198-014-0595-3]
6. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.e42; quiz e30 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001]
7. Lakatos L, Lakatos PL. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med J 2006; 82: 332-337 [PMID: 16679472 DOI: 10.1136/pgmj.2005.042416]
8. Burisch J, Pedersen N, Čuković-Čavka S, Brinar M, Kaimakliotis I, Duricova D, Shonová O, Vind I, Avnstrøm S, Thorsgaard N, Andersen V, Krabbe S, Dahlerup JF, Salupere R, Nielsen KR, Olsen J, Manninen P, Collin P, Tsianos EV, Katsanos KH, Ladefoged K, Lakatos L, Björnsson E, Ragnarsson G, Bailey Y, Odes S, Schwartz D, Martinato M, Lupinacci G, Milla M, De Padova A, D'Incà R, Beltrami M, Kupcinskas L, Kiudelis G, Turcan S, Tighineanu O, Mihu I, Magro F, Barros LF, Goldis A, Lazar D, Belousova E, Nikulina I, Hernandez V, Martinez-Ares D, Almer S, Zhulina Y, Halfvarson J, Arebi N, Sebastian S, Lakatos PL, Langholz E, Munkholm P. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 2014; 63: 588-597 [PMID: 23604131 DOI: 10.1136/gutjnl-2013-304636]
9. Lakatos L, Mester G, Erdelyi Z, Balogh M, Szipocs I, Kamaras G, Lakatos PL. Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. World J Gastroenterol 2004; 10: 404-409 [PMID: 14760767]
10. Lakatos L, Kiss LS, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Lakatos PL. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis 2011; 17: 2558-2565 [PMID: 22072315 DOI: 10.1002/ibd.21607]
11. Gheorghe C, Pascu O, Gheorghe L, Iacob R, Dumitru E, Tantau M, Vadan R, Goldis A, Balan G, Iacob S, Dobru D, Saftoiu A. Epidemiology of inflammatory bowel disease in adults who refer to gastroenterology care in Romania: a multicentre study. Eur J Gastroenterol Hepatol 2004; 16: 1153-1159 [PMID: 15489575]
12. Gregus M. The incidence and prevelance of IBD in Slovakia. Oral presentation. Czech and Slovak IBD conference. Prague 2014
13. Hoivik ML, Bernklev T, Moum B. Need for standardization in population-based quality of life studies: a review of the current literature. Inflamm Bowel Dis 2010; 16: 525-536 [PMID: 19637337 DOI: 10.1002/ibd.21032]
14. Duricova D, Pedersen N, Elkjaer M, Gamborg M, Munkholm P, Jess T. Overall and cause-specific mortality in Crohn's disease: a meta-analysis of population-based studies. Inflamm Bowel Dis 2010; 16: 347-353 [PMID: 19572377 DOI: 10.1002/ibd.21007]
15. Bewtra M, Kaiser LM, TenHave T, Lewis JD. Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis 2013; 19: 599-613 [PMID: 23388544 DOI: 10.1097/MIB.0b013e31827f27ae]
16. Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008; 24: 319-328 [PMID: 18067689 DOI: 10.1185/030079908X260790]
17. Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010; 31: 693-707 [PMID: 20064142 DOI: 10.1111/j.1365-2036.2010.04234.x]
18. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 1471-1478 [PMID: 15361497 DOI: 10.1136/gut.2004.041616]
19. Odes S, Vardi H, Friger M, Wolters F, Russel MG, Riis L, Munkholm P, Politi P, Tsianos E, Clofent J, Vermeire S, Monteiro E, Mouzas I, Fornaciari G, Sijbrandij J, Limonard C, Van Zeijl G, O'morain C, Moum B, Vatn M, Stockbrugger R. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006; 131: 719-728 [PMID: 16952541 DOI: 10.1053/j.gastro.2006.05.052]
20. Rocchi A, Benchimol EI, Bernstein CN, Bitton A, Feagan B, Panaccione R, Glasgow KW, Fernandes A, Ghosh S. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol 2012; 26: 811-817 [PMID: 23166905]
21. van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk CJ, Vermeijden JR, Siersema PD, van Oijen MG, Oldenburg B. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut 2014; 63: 72-79 [PMID: 23135759 DOI: 10.1136/gutjnl-2012-303376]
22. Burisch J. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort. Dan Med J 2014; 61: B4778 [PMID: 24393595]
23. Meder A, ͆wiatkowski M, Meder G, Koza J, Szamocka M. Treatment costs for the group of patients with non-specific inflammatory bowel disease during acute exacerbation and further annual observation. Prz Gastroenterol 2011; 6: 36-44 [DOI: 10.5114/pg.2011.20106]
24. Władysiuk M, Fedyna M, Bebrysz M, Mateusz H, Rutkowski J, Owczarek W, Jahnz-Rozyk K, Gad B, Szmurlo D. Indirect costs of rheumatoid arthritis, Crohn's disease and psoriasis in Poland. Health Technology Assessment International Conference. Washington DC, 2014: 60
25. Mandel MD, Bálint A, Lovász BD, Gulácsi L, Strbák B, Golovics PA, Farkas K, Kürti Z, Szilágyi BK, Mohás A, Molnár T, Lakatos PL. Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ 2014; 15 Suppl 1: S121-S128 [PMID: 24832845 DOI: 10.1007/s10198-014-0603-7]
26. World Bank Databank. Available from: URL: http://databank.worldbank.org/data/home.aspx
27. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991-1030 [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002]
28. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, Danese S, D'Hoore A, Gassull M, Gomollón F, Hommes DW, Michetti P, O'Morain C, Oresland T, Windsor A, Stange EF, Travis SP. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010; 4: 28-62 [PMID: 21122489 DOI: 10.1016/j.crohns.2009.12.002]
29. van Deen WK, van Oijen MG, Myers KD, Centeno A, Howard W, Choi JM, Roth BE, McLaughlin EM, Hollander D, Wong-Swanson B, Sack J, Ong MK, Ha CY, Esrailian E, Hommes DW. A nationwide 2010-2012 analysis of U.S. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis 2014; 20: 1747-1753 [PMID: 25137415 DOI: 10.1097/mib.0000000000000139]
30. National Institute for Health and Clinical Excellence. Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology. Commissioning guide. 2012. Available from: URL: http://www.nice.org.uk/media/F95/42/UpdateTA247AndPsoriasisCG.pdf
31. Bernstein CN, Ng SC, Lakatos PL, Moum B, Loftus EV. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis 2013; 19: 2001-2010 [PMID: 23624887 DOI: 10.1097/MIB.0b013e318281f3bb]
32. Péntek M, Poór G, Wiland P, Olejárová M, Brzosko M, Codreanu C, Brodszky N, Gulácsi L. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur J Health Econ 2014; 15 Suppl 1: S35-S43 [PMID: 24832834 DOI: 10.1007/s10198-014-0592-6]
33. Gulácsi L, Rencz F, Péntek M, Brodszky V, Lopert R, Hevér NV, Baji P. Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. Eur J Health Econ 2014; 15 Suppl 1: S27-S34 [PMID: 24832833 DOI: 10.1007/s10198-014-0591-7]
34. Eurostat Statistics Database. Available from: URL: http://epp.eurostat.ec.europa.eu/portal/page/portal/statistics/search-database
35. Gulácsi L, Rotar AM, Niewada M, Löblová O, Rencz F, Petrova G, Boncz I, Klazinga NS. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur J Health Econ 2014; 15 Suppl 1: S13-S25 [PMID: 24832832 DOI: 10.1007/s10198-014-0590-8]
36. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009; 30: 265-274 [PMID: 19438428 DOI: 10.1111/j.1365-2036.2009.04033.x]
37. Chaudhary MA, Fan T. Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands. Biol Ther 2013; 3: 45-60 [PMID: 24392304 DOI: 10.1007/s13554-012-0007-0]
38. Loftus EV, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM. Costeffectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2009; 21: 1302-1309 [PMID: 19465858 DOI: 10.1097/MEG.0b013e32832a8d 71]
39. Punekar YS, Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. Eur J Health Econ 2010; 11: 67-76 [PMID: 19844750 DOI: 10.1007/s10198-009-0199-5]
40. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health 2009; 12 Suppl 1: S5-S9 [PMID: 19250132 DOI: 10.1111/j.1524-4733.2009.00515.x]
41. Goszczynska K, Wrona W, Niewada M, Black CM, Fan T, Lobodzinski P. Cost-effectiveness of infliximab versus colectomy for the treatment of severe active ulcerative colitis in Poland. Value Health 2013; 16: A213-214
42. Hanova P, Pavelka K, Dostal C, Holcatova I, Pikhart H. Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002-2003. Clin Exp Rheumatol 2006; 24: 499-507 [PMID: 17181917]
43. Lepp-Gazdag A, Gulácsi L, Brandtmüller Á. A rheumatoid arthritis megbetegedés és ellátás jellemzo″i Magyarországon. Egészségügyi Gazdasági Szemle 2002; (6): 645-657
44. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004; 63: 4-10 [PMID: 14672883]
45. Bitter J, Hulec J. [Ulcerative colitis in the North Bohemian Region]. Cesk Gastroenterol Vyz 1980; 34: 137-144 [PMID: 7388984]
46. Nedbal J, Maratka Z. [Ulcerative colitis in Czechoslovakia]. Vnitr Lek 1967; 13: 1054-1063 [PMID: 6081667]
47. Salupere R. Inflammatory bowel disease in Estonia: a prospective epidemiologic study 1993-1998. World J Gastroenterol 2001; 7: 387-388 [PMID: 11819795]
48. Kull K, Salupere R, Uibo R, Ots M, Salupere V. Antineutrophil cytoplasmic antibodies in Estonian patients with inflammatory bowel disease. Prevalence and diagnostic role. Hepatogastroenterology 1998; 45: 2132-2137 [PMID: 9951879]
49. Nagy G, Ujszaszy L, Juhasz L, Minik K. Epidemiology of inflammatory bowel diseases in Borsod-Abauj-Zemplen county 1963-1992. Lege artis Med 1994; 4: 424-430
50. Zvirbliene A, Kiudelis G, Kupcinskas L. [Retrospective analysis of case histories of patients with ulcerative colitis and Crohn's disease]. Medicina (Kaunas) 2003; 39: 745-750 [PMID: 12960453]
51. Kiudelis G, Jonaitis L, Adamonis K, Zvirblienë A, Tamelis A, Kregždytë R, Kuèinskienë R, Šventoraitytë J, Kupèinskas L. Incidence of inflammatory bowel disease in Kaunas region, Lithuania. Medicina (Kaunas) 2012; 48: 431-435 [PMID: 23128464]
52. Chojecki Z. Epidemiology of Ulcerative Colitis in Poland. Pol Med Sci Hist Bull 1964; 7: 53-56 [PMID: 14152252]
53. Wiercinska-Drapalo A, Jaroszewicz J, Flisiak R, Prokopowicz D. Epidemiological characteristics of inflammatory bowel disease in North-Eastern Poland. World J Gastroenterol 2005; 11: 2630-2633 [PMID: 15849823]
54. Gheorghe L, Gheorghe C, Aposteanu G. Clinical patterns and disease distribution in Crohn's disease in relationship to age at diagnosis. Rom J Gastroenterol 1997; (6): 147-152
55. Toader EI. Inflammatory bowel disease - a public health problem. J Prev Med 2008; 16: 33-45
56. Príkazská M, Letkovicová M. [Crohn's disease in the adult population in Slovakia]. Bratisl Lek Listy 1996; 97: 230-233 [PMID: 8689331]
57. Príkazka M, Letkovicová M, Matejíckova V. Crohns disease in Slovakia: prevalence, socioeconomic and psychological analysis. Eur J Epidemiol 1998; 14: 49-53 [PMID: 9517873]